Perioperative development of a thrombogenic risk profile in patients with carcinomas of the breast: A cause of increased thrombosis

European Journal of Gynaecological Oncology

Volumn 21, Issue 6, 2000, Pages 560-568

  Oberhoff, C ^a   Rollwagen, Ch ^a   Tauchert, A M ^a   Hoffmann, O ^a   Winkler, U H ^a   Schindler, A E ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Breast cancer; Haemostasis; Surgery; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 8; D DIMER; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGE; AGED; ANTICOAGULATION; BLOOD CLOTTING; BREAST CARCINOMA; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MENOPAUSE; PATIENT MONITORING; PERIOPERATIVE PERIOD; RISK FACTOR; SMOKING; THROMBOGENESIS; THROMBOPHILIA; THROMBOSIS;

ADULT; BLOOD COAGULATION; BREAST DISEASES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FIBRINOLYSIS; HUMANS; MASTECTOMY; MIDDLE AGED; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 0034468294     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Einfluß operativer eingriffe auf das gerinnungs- und fribrinolyse-system bei verschiedenen gynäkologischen erkrankungen
2. Todesursachen bei Malignompatienten
3. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
4. Surgical morbidity after mastectomy operations
5. Influence of aging on the activity of the hemostatic system: Prothrombin fragment 1+2, thrombin-antithrombin III complex and D-dimers in 80 healthy subjects with age ranging from 20-94 years
6. Thromboembolic accidents in postmenopausal patients treated by tamoxifen as adjuvant treatment. Frequency, risk factors and prevention
7. Fibrinolytic shut-down after surgery: Impairment of the balance between tissue-type plasminogen activator and its specific inhibitor
8. Cancer and thrombosis: From phlegmasia alba dolens to trangenic mice
9. Thrombosis and cancer
10. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
11. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery
12. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors
13. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer
14. Evaluation of some hemostatic parameters in patients with cervical carcinoma
15. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma
16. Increased incidence of thromboembolism in Stage IV breast cancer patients treated with a five-drug chemotherapy regimen - A study of 159 patients
17. Cancer cell procoagulants and their role in malignant disease
18. Detection and relevance of crosslinked fibrin derivates in blood
19. Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay
20. Low-dose-heparin versus nieder-molekulares heparin zur thrombose-prophylaxe in der operativen gynækologischen onkologie
21. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant coloretal disease - A preliminary study
22. Soluble fibrin in plasma before and after surgery for benign and malignant colorectal disease
23. The postoperative fibrinolytic shutdown: A rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-typeplasminogen activator after trauma
24. Update 1996: Blood collection and handling proceduces for assessment of plasminogen activators and inhibitors (Leiden Fibrinolysis Workshop)
25. Leiden fibrinolysis working party: Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1)
26. Major operations, hemostatic parameters and venous thrombosis
27. Alterations in fibrinolysis associated with surgery and venous thrombosis
28. The relevance of plasminogen activators to neoplastic growth
29. Coagulation disturbances in cancer of the breast and colon measured with specific monoclonal antibody enzyme immunoassay for fibrin-fibrinogen degradation products
30. Antithrombin III and procoagulant activity: Sex differences and effects of the menopause
31. Postoperative decrease of protein C and hypercoagulability
32. Hemostasis in malignancy
33. Hemostatic abnormalities in untreated cancer: Incidence and correlation with thrombotic and hemorrhagic complications
34. Multiple forms of plasminogen activator in human breast tumors
35. The pathophysiology of thrombosis in cancer
36. Combination chemotherapy with mastectomy or radiotherapy for stage III breast cancer: A cancer and leukemia group B study
37. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer
38. Frequency of malignant disease in deep venous thrombosis of the lower extremities
39. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen
40. Tumour-associated fibrinolysis: The prognosis relevance of plaminogen activators uPA and tPA in human breast cancer
41. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer
42. The risk of a diagnosis of cancer after primary deep vein thrombosis or pulmonary embolism
43. Complications and hospital stay after surgery for breast cancer: A prospective study of 385 patients
44. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism
45. Deep vein thrombosis and changes m coagulation and fibrinolysis after gynecological operations in Chinese: The effect of oral contraceptives and malignant disease
46. Consommation de tabac et risque cardiovasculaire
47. Non-tumor morbidity and mortality after modified radical mastectomy
48. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer